This exciting finding opens the way for the development of new antibacterial drugs to fight bacteria using their own weapons.
A new study which was performed jointly at Umeå University and the University of Washington in Seattle, USA, discovered that bacteria can degrade the cell membrane of bacterial competitors with enzymes that do not harm their own membrane. This exciting finding opens the way for the development of new antibacterial drugs to fight bacteria using their own weapons.
During the infection of a host organism, pathogenic bacteria can excrete toxins that cause damage to host cells and tissue. Interestingly, bacteria also use similar mechanisms in competition with one another. Notably, they can use secretion systems with syringe-like structures to inject the toxins into other cells. Among the different secretion systems that are known in bacteria, the type VI secretion system is of particular importance to interbacterial competition, and is found in many different species of bacteria. The collaborating Swedish-American research teams now found that certain enzymes, phospholipases, are secreted by the type VI system and that they are only effective against the competitor but not the producer’s own cell membrane.
Sun Nyunt Wai, professor at the Laboratory for Molecular Infection Medicine Sweden (MIMS) and the department of Molecular Biology in Umeå, Sweden, and Joseph D. Mougous, professor at the University of Washington, Seattle, USA, studied together with their students and post-docs the genes and proteins that are behind this selective defence mechanism. They studied the type VI secretion systems in Pseudomonas aeruginosa, soil bacteria causing severe infections of intestines, blood and lungs, and in Vibrio cholerae, a pathogen causing the life-threatening cholera diarrhea.
– Bacteria have evolved many strategies for defence against predators and competitors in the environment. In this study we found that the bacteria possess phospholipases, that degrade a major phospholipid component in the cell membranes, Sun Nyunt Wai, said. And we found that the bacteria producing the antibacterial effector at the same time produced an immunity protein that protects them against their own toxin. Her student Krisztina Hathazi and postdoctoral fellow Takahiko Ishikawa participated in the studies and are co-authors of the report in Nature.
When the team tested their hypothesis with mutants lacking the genes for immunity, they found that membrane integrity was greatly impaired, as the bacterial cells were now harmed by self-intoxication.
– The finding that bacterial phospholipases, classically considered potent mediators of virulence, can also serve as offensive weapons against competing bacteria was really quite surprising and challenges basic assumptions made concerning these enzymes, commented PhD student Alistair B. Russell, the first author of the report.
The Latest Bing News on:
Antibacterial drugs
- Cats And Dogs Can Spread Antibiotic Resistant Superbugs To Ownerson April 27, 2024 at 10:55 am
Transfer of bacteria between sick pets and their humans may be contributing to antibiotic resistance, according to new research.
- FDA Approves New Antibiotic for Uncomplicated UTIson April 26, 2024 at 11:54 am
The US Food and Drug Administration has approved pivmecillinam (Pivya) tablets to treat uncomplicated urinary tract infections in women.
- Vaccines have a crucial role in tackling antimicrobial resistanceon April 26, 2024 at 10:04 am
Antimicrobial resistance is a leading cause of death and disability worldwide. In 2019, it caused over 1 million deaths globally and was linked to almost 5 million.
- Common antibiotic Neosporin may shield against viral respiratory infectionson April 26, 2024 at 9:00 am
A study conducted first in mice and then in human volunteers suggests that a common antibiotic, neomycin, which is the main active ingredient in Neosporin, may help protect against viral respiratory ...
- Study: Antibiotic use in moderate COVID-19 linked to clinical deteriorationon April 26, 2024 at 7:56 am
Antibiotic treatment of adults hospitalized with moderate COVID-19 is associated with clinical deterioration, despite the drugs being given to over 40% of patients, according to new research being ...
- What to Know About Pivya, the New Antibiotic Treatment for UTIson April 26, 2024 at 4:06 am
The Food and Drug Administration recently approved Pivya (pivmecillinam) to treat uncomplicated UTIs in female adults. Clinical trials show that Pivya is effective and side effects are limited.
- Climate change fuels the rise of global antimicrobial resistanceon April 25, 2024 at 10:34 am
Climate change exacerbates antimicrobial resistance by altering environments where microbes thrive, leading to increased disease spread.
- FDA approves new antibiotic against UTIson April 25, 2024 at 8:10 am
"The FDA is committed to fostering new antibiotic availability when they prove to be safe and effective, and Pivya will provide an additional treatment option for uncomplicated UTIs," he added.
- What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fallon April 25, 2024 at 8:07 am
The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes ...
- F.D.A. Approves Antibiotic for Increasingly Hard-to-Treat Urinary Tract Infectionson April 24, 2024 at 1:45 pm
Pivmecillinam, which has been used in Europe for decades, will become available next year to women 18 and older.
The Latest Google Headlines on:
Antibacterial drugs
[google_news title=”” keyword=”antibacterial drugs” num_posts=”10″ blurb_length=”0″ show_thumb=”left”] [/vc_column_text]The Latest Bing News on:
Bacterial phospholipases
- Feed has no items.
The Latest Google Headlines on:
Bacterial phospholipases
[google_news title=”” keyword=”bacterial phospholipases” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]